Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Resectable Non-Small Cell Lung Cancer

Inclusion Criteria:

1. Histologically or cytologically confirmed, previously untreated and surgicallyresectable non-small cell lung cancer (stage II-IIIA, patients with squamous cellcarcinoma or EGFR mutation should not be included);

2. Eastern Cooperative Oncology Group (ECOG) performance status 0-1;

3. Satisfactory preoperative laboratory testing and adequate pulmonary function forsurgery;

4. Patients approve and sign the informed consent.

Exclusion Criteria:

1. Pancoast tumor, squamous cell carcinoma, large-cell carcinoma and sarcomatoidcarcinoma;

2. Patients with active autoimmune disease or history of autoimmune disease;

3. Patients who have a condition requiring systemic treatment with either prednisone orother immunosuppressive medications;

4. Patients with a history of symptomatic interstitial lung disease;

5. History of allergy to study drug components;

6. Women must not be pregnant or breast-feeding;

7. Men with female partners that are not willing to use contraception;

8. Patients who have received prior chemotherapy, anti-angiogenesis therapy andimmunotherapy for this malignancy or for any other past malignancy;

9. Patients who have received prior treatment for non-small cell lung cancer;

10. Any mental or psychological condition which would not permit the patient to completethe study or understand the patient information;

11. Patients who have major hemoptysis within the past 4 weeks, tumor has invasion or isclose to great vessels;

12. Patients with high risk of major bleeding;

13. Patients who have arterial thrombotic events, esophageal varices, peptic ulcers,wounds or bone fractures;

14. Patients who have prior malignancies;

15. HIV, HBV, HCV infection or active pulmonary tuberculosis;

16. Underlying medical conditions that, in the Investigator's opinion, will make theadministration of study drug hazardous or obscure the interpretation of toxicity oradverse events.